RT Journal Article
SR Electronic
T1 Predicting emergent Dolutegravir resistance in South Africa: A modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.20.24310740
DO 10.1101/2024.07.20.24310740
A1 Loosli, Tom
A1 Hauser, Anthony
A1 Josi, Johannes
A1 Han, Nuri
A1 Ingle, Suzanne M
A1 van Sighem, Ard
A1 Wittkop, Linda
A1 Vehreschild, Janne
A1 Ceccherini-Silberstein, Francesca
A1 Maartens, Gary
A1 Gill, M John
A1 Sabin, Caroline A
A1 Johnson, Leigh F
A1 Lessells, Richard
A1 Günthard, Huldrych F
A1 Egger, Matthias
A1 Kouyos, Roger D
YR 2024
UL http://medrxiv.org/content/early/2024/07/21/2024.07.20.24310740.abstract
AB Background In response to the rising prevalence of non-nucleoside reverse transcriptase inhibitors (NNRTIs) resistance, millions of people living with HIV (PWH) have switched to dolutegravir-based antiretroviral therapy (ART). Understanding the possible emergence of dolutegravir resistance is essential for health policy and planning. We developed a mathematical model to predict the trends of dolutegravir resistance in PWH in South Africa.Methods MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a deterministic compartmental model consisting of four layers: (i) the cascade of care, (ii) disease progression, (iii) gender, and (iv) drug resistance. MARISA was calibrated to reproduce the HIV epidemic in South Africa. We assumed dolutegravir was introduced in 2020. We extended the model by including key resistance mutations observed in PWH experiencing virologic failure on dolutegravir-based ART (G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K). Model outcomes were acquired (ADR) and transmitted drug resistance (TDR) to dolutegravir and NNRTIs stratified by duration on failing dolutegravir-based ART and under different counterfactual scenarios of switching to protease-inhibitor (PI)-based ART.Finding The model predicts that ADR will increase rapidly, from 18.5% (uncertainty range 12.5% to 25.4%) in 2023 to 46.2% (32.9% to 58.9%) in 2040. The prevalence of ADR in 2040 increased with the duration of virologic failure on dolutegravir-based ART: 18.0% (12.2% to 23.7%) for 6 months of failing ART compared to 54.8% (41.1% to 63.9%) for over 1.5 years. For TDR, the model predicts a slow but steady increase from 0.1% (0.1% to 0.2%) in 2023 to 8.8% (4.4% to 17.3%) in 2040. Transmitted NNRTI resistance will cease to increase but remain prevalent at 7.7% in 2040. Rapid resistance testing-informed switching to PI-based ART would substantially reduce both ADR and TDR.Interpretation The prevalence of dolutegravir ADR and TDR will likely increase, with the 10% threshold of TDR possibly reached by 2035, depending on monitoring and switching strategies. The increase will likely be greater in settings where resources for HIV-1 RNA monitoring and resistance testing or options for switching to alternative ART regimens are limited.Funding Swiss National Science Foundation, National Institutes of Health, UZH URPP Evolution in ActionEvidence before this study Dolutegravir has demonstrated high efficacy, even in individuals with compromised backbone drugs. We searched Scopus on April 15 2024, using free text words dolutegravir and resistance. We did not identify any modelling studies attempting to predict dolutegravir resistance trends in the coming years. A recent collaborative analysis of predominantly European cohort studies involving 599 people living with HIV (PWH) who underwent genotypic resistance testing at the point of dolutegravir-based treatment failure showed that the risk of dolutegravir resistance increases significantly in the presence of Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance. This is particularly concerning in settings such as South Africa, where a high proportion of individuals already exhibit NRTI resistance. Indeed, recent surveys in South Africa already hint at rapidly increasing levels of acquired dolutegravir resistance.Added value of this study This study is the first to model the likely dynamics of dolutegravir resistance in South Africa. Covering the period 2020 to 2040, it extends a previous model of antiretroviral drug resistance evolution in South Africa to dolutegravir-based ART. The results indicate that while dolutegravir resistance is currently low, it will increase at the population level, and transmitted dolutegravir resistance may exceed 10% by around 2035, depending on the duration PWH spend on failing dolutegravir-based ART. Interventions such as switching to protease-inhibitor (PI)-based ART based on genotypic resistance tests could reduce or even curb the rise of dolutegravir resistance.Implications of all the available evidence Dolutegravir resistance may undermine the success of integrase strand transfer inhibitor (INSTI)-based ART in South Africa, where the guidelines limit drug resistance testing to PWH with repeated viral load measurements above 1,000 copies/mL and evidence of good adherence. Monitoring the evolution of dolutegravir resistance at the population level is crucial to inform future changes in guidelines on drug resistance testing and switching to PI-based ART.Competing Interest StatementDeclaration of interests RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead Sciences. MJG has served as an ad hoc advisor to Gilead, ViiV and Merck. RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead Sciences. H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, Zurich Primary HIV Infection, Systems.X, Bill and Melinda Gates Foundation, NIH, Gilead Sciences, ViiV and Roche; personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and Novartis for consultancy or data and safety monitoring board membership; and a travel grant from Gilead. LW has received grants from the ANRS emerging infectious diseases ANRS MIE, European Union (projects funded via H2020, Horizon Europe). SMI reports grant funding by the NIH National Institute on Alcohol Abuse and Alcoholism (U01-AA026209, payment to institution). F.C.S has received grants from the Italian Istituto Superiore di Sanita, Italian Ministry of Health, Italian Ministry of University and Scientific Research, University of Rome Tor Vergata, European Union (projects funded via H2020, Horizon Europe), ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc.; personal fees for consultancy from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc. All other authors declare no competing interests.Funding StatementThis work was supported by the University Research Priority Program Evolution in Action, the Swiss National Science Foundation (324730_207957), and the NIH National Institute of Allergy and Infectious Diseases under award number R01AI152772. We thank the DTG RESIST study group for helpful discussions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees or institutional review boards approved the eight individual cohorts, which each used standardised data collection methods and regularly followed up participants who consented to be included. The Ethics Committee of the Canton of Bern, the Ethics Committee of the University of Cape Town and the local ethics committees or institutional review boards all approved the use of routine clinical data for research within the IeDEA collaboration. No specific additional ethics approval was required for this analysis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or the appendix.